Biopharmaceutical company developing therapies for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases.
Terns Pharmaceuticals, Inc., a dynamic clinical-stage biopharmaceutical company headquartered in Foster City, California, is dedicated to advancing therapeutic solutions for non-alcoholic steatohepatitis (NASH) and obesity. The company specializes in developing innovative small-molecule therapies, both as single agents and in combination regimens, to address these challenging medical conditions.
At the forefront of Terns Pharmaceuticals' pipeline is TERN-101, a novel farnesoid X receptor agonist designed for targeted distribution in the liver and devoid of bile acid properties. Currently in Phase IIa clinical trials, TERN-101 aims to effectively treat NASH by modulating key biological pathways associated with liver inflammation and metabolic dysfunction.
Additionally, the company is advancing TERN-201, an inhibitor of vascular adhesion protein-1, through Phase Ib clinical trials for NASH treatment. This candidate aims to mitigate liver inflammation and fibrosis, addressing critical aspects of the disease's progression.
Further expanding its innovative portfolio, Terns Pharmaceuticals is dewveloping TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution, currently in Phase I clinical trials for NASH. The company also pursues TERN-601, a promising Glucagon-Like Peptide-1 receptor agonist program intended for oral administration to treat NASH and metabolic diseases like obesity, positioning Terns Pharmaceuticals at the forefront of therapeutic innovation in these challenging medical fields.